Why did Krsnaa Diagnostics (KRSNAA) stock move recently?

On 8/5/2026, Krsnaa Diagnostics moved +3.8% — No clear company-specific catalyst identified; the stock moved with the broader market or sector. This is MarketChacha's decoded reason from filings and credible news; it is education, not buy/sell advice.

Is Krsnaa Diagnostics (KRSNAA) overvalued or fairly valued?

MarketChacha shows Krsnaa Diagnostics's valuation in context — a forward P/E of about 12.7, a price-to-book of about 1.9 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

What is Krsnaa Diagnostics's revenue?

Krsnaa Diagnostics reported revenue of ₹691 Cr for FY2026, with net profit of ₹103 Cr, per official filings.

What is the share price of Krsnaa Diagnostics (KRSNAA)?

Krsnaa Diagnostics last traded at ₹574.80 (+2.5% on the day), as of 8/11/2026 — a delayed quote shown for education, not investment advice.

Krsnaa Diagnostics

KRSNAA · NSE · Healthcare · India

Snapshot

TickerKRSNAA

ExchangeNSE

SectorHealthcare

IndustryDiagnostics & Research

CountryIndia

CEOMr. Mitesh Dave

HeadquartersPune, India

Websitekrsnaadiagnostics.com

Filings tracked2

About Krsnaa Diagnostics

Krsnaa Diagnostics Limited provides diagnostic services in India. It offers a range radiology services, including computed tomography scans, magnetic resonance imaging, X-rays, and ultrasound and advanced imaging; pathology services, such as laboratory, and home collection and preventive health; and teleradiology and telepathology services. The company also provides other diagnostics services, such as ophthalmic test, mammography, dental imaging, stress test, dual-energy X-ray absorptiometry scan, and bone mineral density test. It serves individual patients, government clients, corporate clients, hospitals, clinics, private practitioner, and other healthcare providers. Krsnaa Diagnostics Limited was incorporated in 2010 and is based in Pune, India.

Who owns it

Promoters45.7%
Institutions13.5%
Public & other40.8%

12 institutional holders

Ownership breakdown from public market data. Promoter pledge is not included here — that comes from exchange shareholding filings.

Forensic scorecard

No major accounting red flags in the fundamentals we have — profit is backed by cash and returns look healthy.

Net margin trend12.8% → 13.1%

Margin has held broadly steady over the period — stable profitability.

Growth qualityrev 12% · PAT 13%

Profit growth is broadly tracking revenue growth — the earnings trend looks operational rather than one-off.

Computed by MarketChacha from reported figures (Yahoo Finance). Education, not a rating or recommendation.

What's expected next

Next fiscal year

Rev ₹1,129 Cr · EPS 45.25

Est. earnings growth +51.0%

Analyst consensus estimates — not the company's own guidance.

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: Yahoo Finance

Annual

Quarterly · last 4

Revenue (FY2026)

₹773 Cr

Net margin

13.1%

Revenue CAGR (3y)

+16.6%

Profit CAGR (3y)

+17.8%

Net profit (FY2026)

₹101 Cr

Ask MarketChacha about KRSNAA

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Why it moved

Aug 5, 2026
No clear company-specific catalyst identified; the stock moved with the broader market or sector.
· confidence: low
Aug 4, 2026
No clear company-specific catalyst found in recent filings or credible news coverage for the 7.27% gain; the July 23 Himachal tender update is over a week old and earnings are scheduled for Aug 5.
· confidence: low

Daily moves with the verified reason behind them. Education only — not investment advice.

Financials

Yearly

Period	Revenue	Net profit	Net margin
FY2026	₹773 Cr	₹101 Cr	13.1%
FY2025	₹717 Cr	₹78 Cr	10.8%
FY2024	₹620 Cr	₹57 Cr	9.2%
FY2023	₹487 Cr	₹62 Cr	12.8%

Quarterly

Period	Revenue	Net profit	Net margin
Q4 FY26	₹193 Cr	₹42 Cr	21.7%
Q3 FY26	₹181 Cr	₹15 Cr	8.4%
Q2 FY26	₹206 Cr	₹24 Cr	11.6%
Q1 FY26	₹193 Cr	₹21 Cr	10.6%

Figures as reported, in ₹ (crore). Source: Yahoo Finance.

Filings & announcements

2026

Board Meeting Intimation for Consideration And Approval Of The Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter Ended June 30, 2026 And Fund Raising.
Krsnaa Diagnostics Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/08/2026 ,inter alia, to consider and approve the unaudited standalone ....
BSE8/7/2026material
Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015- Update On Himachal Tender
Intimation for signing of agreement with Authority
BSE7/23/2026

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.